Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition Improves Left Ventricular Function and Reduces Adverse Left-Ventricular Remodeling in High-Risk Patients with Microvascular Obstruction (MVO) Following ST-elevation Myocardial Infarction (STEMI).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Sarah Schwager, RN
- Phone Number: 612-863-3833
- Email: sarah.schwager@allina.com
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Recruiting
- Minneapolis Heart Institute Foundation
-
Contact:
- Sarah Schwager, RN
- Phone Number: 612-863-3833
- Email: sarah.schwager@allina.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with their first STEMI (>18 years) who underwent successful primary PCI and able to give informed consent
- At least mild LV dysfunction (LVEF < 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI
- Infarct size that is > 10% of LV mass
- The presence of MVO that is > 10% of infarct size
Exclusion Criteria:
- Contraindication to cardiac MRI
- Life expectancy < 1 year
- Previous CABG or Valve Surgery
- Previous STEMI
- Pregnant or planning to become pregnant or lactating women
- Cardiogenic shock (not resolved)
- Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding PVCs)
- GFR<30 ml/min/1.73m2 or end-stage renal disease on dialysis
- Type 1 diabetes mellitus or history of diabetic ketoacidosis
- Type I or II diabetes with insulin use
- Prior intolerance of SGLT2 inhibitors
- Current use of SGLT2 inhibitors (randomized patients only)
- Contraindications to gadolinium
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo Group
Placebo Group will receive placebo in addition to standard heart attack medications for the duration of hospitalization and 6-month duration of the study.
|
Placebo once daily for six months
|
|
Active Comparator: Treatment Group
Treatment group will receive SGLT2 inhibitor in addition to standard heart attack medications for the duration of hospitalization and 6-month duration of the study.
|
SGLT2 inhibitor once daily for six months
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in LVESVI
Time Frame: 6 Months
|
Change in LVESVI at 6 months as measured by MRI.
|
6 Months
|
|
Change in LVEDVI
Time Frame: 6 Months
|
Change in LVEDVI at 6 months as measured by MRI.
|
6 Months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in LV mass
Time Frame: 6 months
|
Change in LV mass at 6 months as measured by cMRI
|
6 months
|
|
Change in LVEF
Time Frame: 6 months
|
Change in LVEF at 6 months as measured by cMRI
|
6 months
|
|
MACE rates - including hospitalization for CHF, repeat revascularization, MI and death and ICD implantation
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jay Traverse, MD, Minneapolis Heart Institute Foundation
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Pathological Conditions, Anatomical
- Infarction
- Hypertrophy
- Myocardial Infarction
- Cardiomegaly
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Sodium-Glucose Transporter 2 Inhibitors
Other Study ID Numbers
Other Study ID Numbers
- 1852152
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.